Tag: Grindeks

Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The company specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
The Grindeks’ Group consists of 5 subsidiary companies in Latvia, Estonia, Russia and Slovakia; representative offices are opened in 13 countries.
Grindeks’ products are exported to 70 countries with export comprising 90% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam. Company’s shares are listed on the Official List of Nasdaq Riga.

Sold in 70 countries worldwide, Grindeks’ product portfolio is successfully composed of branded products, generic medications and active pharmaceutical ingredients, all produced in line with the world class requirements of safety and quality.

Grindeks is a worldwide Active Pharmaceutical Ingredients (APIs) supplier due to quality, modern manufacturing units and global regulatory accreditation. APIs are produced according to GMP requirements, certified by Authorization (licence) for API manufacturing and Certificate of GMP compliance of manufacturer.

AS Grindeks (branded as Grindex), is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.

One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate. Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.

In 2015, Grindeks had a turnover revenue of €82.7 million with a profit of €1.0 million. Grindeks had 883 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anna Lipmane (16.65%).

Grindeks and the Institute of Organic Synthesis of Latvia to develop a new drug

The agreement on cooperation between the pharmaceutical company Grindeks and the Latvian Institute of Organic Synthesis is related to work on a new drug.

Grindeks anticipates at least 10% turnover increase in 2018

JSC Grindeks is expecting to reach at least 10% increase in turnover in 2018. The turnover growth will be reached by raising export volume and entering new markets

Grindex received a Russian GMP certificate

JSC Grindex received a Russian GMP certificate and thus demonstrated that its quality system meets all relevant legal requirements of one of the most important markets.

Grindex will invest 1 billion rubles in a new plant in the Ulyanovsk region

Grindex will invest more than a billion rubles in a plant for manufacturing the antitumor agents in the Ulyanovsk regio

Grindeks raised its profit in Q1 of 2017

JSC “Grindeks” submitted the non-audited consolidated financial statements for the first three months of 2017 to “Nasdaq Riga”

Two Grindeks subsidiaries receive Russian GMP certificates

Quality director of JSC Grindeks, Dr.chem. Juris Hmeļņickis points out that receiving GMP certificates is a positive development for the whole Grindeks Group and it will contribute to export to Ru...